CURRICULUM VITAE
Gunnar C.
Hansson
Address
work:
University
of Gothenburg
Department of Medical
Biochemistry and Cell Biology
Box
440/Medicinaregatan 9
S-405
30 Gothenburg, SWEDEN
Social:
Married,
3 children (1979, 1982, 1990)
Basic education:
Studentexamen
(Gymnasium) Växjö (natural sciences) 1970
Medical
education and licence:
M.D.
(läkarexamen) 1976
Licence
to practice medicine in
Physician
for about 3 years in chronic illnesses clinic, ear-nose-throat clinic,
paediatrics, blood bank, psychiatry, surgery, internal medicine. and emergency
room at out-patient.
Scientific
training:
-Part
time 1972‑1976, Full time 1976‑1981
-PhD. (medicine doktorsexamen) 1981
-Docent in Medical and
Physiological Chemistry (Medical Biochemistry) 1983
Abroad:
1983-1984
Post-doc, National Institute of Health,
1998-
1999 Sabbatical with John R. Riordan (discoverer of CFTR) and Sandra J. Gendlet, Mayo Foundation;
Scientific
positions:
-Post-doc.
position (forskarassistent) 1984-1987 at the
Department of Medical Biochemistry
-Associate
professor (Senior Lecturer) of Molecular Biology at the Medical Faculty of Göteborg University, 1987-1996. Permanent-tenured position (universitetslektor).
Professorships
-Appointed as Associate Professor (‘Biträdande professor’)
in Molecular Biology University
of Gothenburg, 1996-1998
-Full
professor of Medical Biochemistry (medicinsk och fysiologisk kemi), Department
of Medical Biochemistry, University of Gothenburg, 1998 - present.
Teaching:
Long
experience of teaching at undergraduate (Medical school, Dental school,
Pharmacy).
Member of:
·
The
Royal Academy of Sciences (medicine) (KVA) corresponding
to National Academy of Sciences USA 2015 –
·
Honorary
Chemist in Royal Academy of Sciences (chemistry) for Nobel Price Evaluation
·
The
Royal Society of Arts and Sciences in Gothenburg (KVVS) 2012 –
Prices-Awards:
·
Axel Hirsch price, Karolinska Institutet, Stockholm
2018
·
The
Royal Swedish King Medal 8th size with Serafimer ordens ribbon for meritorious achievements in Medical
Research, especially Cystic Fibrosis, 2021
Scientific
accomplishments, for Bibliography, see separate list:
2022,
2023, and 2024 among 1% most cited scientist in cross-field area
according to Clarivate.
Published
>310 scientific publications.
From
Clarivate, h-index 78 (Oct 2024).
Most
cited publication: The inner
of the two Muc2 mucin dependent mucus layers in colon is
devoid of bacteria. Proc. Natl. Acad. Sci USA, 105, 15064-15069 Cited 1447
times today and stadily >100/year.
Founder of
the Consortia of Mucin Biology Groups (MBG), presently with 9 independent PIs and groups.
Totally about 30 scientists from 3 different Departments Biochemistry-Cell
Biology, Physiology, and Medicine.
Scientific
Focus
Since
late 1980ies focus on mucins and mucus including glycans and protein with a
focus on normal function and diseases of the gastrointestinal tract and for the
last 7-8 years focus on the respiratory tract. Today a leading scientist in
understanding biosynthesis, structure, and function of mucins and related
proteins found in mucus.
Organisation of
international meetings, selected:
-Mucus
and mucins, Gothenburg 1995. About 150 participants.
-Mass spectrometry in
biology, Hindås 1997. About 50 participants.
-XIIIth Interantional Cystic
Fibrosis Congress, Stockholm 2000, About 1500 participants
-Innate immunity in the
gastrointestinal tract, October 2003, About 90 participants
-CFTR in the
gastrointestinal tract, November 2005, About 90 participants
-Vice-chairman
for FEBS 2010, joint meeting organized by Sweden-Norway in Gothenburg
-Vice-chairman
for European Cystic Fibrosis Conference 2014, Gothenburg
-Nordic
Glycobiology meeting, 2017 Gothenburg. 100 participants
-Royal
Academy of Sciences “Next challenge-Impact of Glycosylation”,
Nov. 11, 2019, Lund. 150 participants
Science Policy
Article
on funding of medical research in Dagens Nyheter, main Swedish newspaper, 2001
On Cystic Fibrosis,
Svenska Dagbladet 2018 and 2022
Current major
external funding:
· Wallenberg Foundation, 2017-2024, SEK
5 800 000/year for 5 years,
Molecular structure of mucin domains and
roles of their interactions in mucus of the intestinal and respiratory
diseases.
· ERC Proof of Concept 2023-2024, €150,000, Novel treatments for the mucus accumulation at chronic lung diseases.
· The
Swedish Science Research Council 2024-2026; SEK 1 800 000/year for 3 years; Biochemistry and function of mucins and related
molecules in diseases of the respiratory tract. Highest score possible.
· LUA/ALF, Mucus in Diseases - COPD,
Cystic Fibrosis, Crohn’s, and IBS, 2022-2024, SEK 1 000 000/year
Finished (major)
· Melinda and Bill Gates Foundation 2019-2022, USD 749,770 for 3 years, In Vitro and In Vivo Mucus Screen for LOPAC
and Natural Product Libraries. Finished June 30, 2022
·
The Swedish Science Research Council
2018-2023; SEK 1 800 000/year for 5 years; Biochemistry
and function of mucins and related molecules in the respiratory and
gastrointestinal tracts. Highest score possible.
· European Research Council, 2016 – 2021, Advanded
ERC, SEK 4 800 000/year for 5 years, The role of mucins and mucus in the diseases
cystic fibrosis, ceoliac disease and ulcerative
colitis.
· National Institute of Allergy and Infectious Diseases, National Institue of Health (NIH) 2016-2021 USD 305 614/year for 5
years. The MUC2 Mucus Gel as an Innate
Immune Mechanisms that Inhibits Colitis
· NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH 2012-2016 USD
300 000/year for 5 years. The MUC2 Mucus
Gel as an Innate Immune Mechanisms that Inhibits Colitis
· Wallenberg Foundation, 2012-2017, SEK 28 000 000 for 5 years, The mucus layer formed by the MUC2 mucin as the
habitat of the colon commensal microbiota
· The
Swedish Foundation for Strategic Research, 2010-2015, SEK 30 000 000 for 5
years, The colon mucus layers as the first innate immune barrier.
Supervision of PhD.- completed thesis
(year of graduation and current position)
1. Dan Baeckström 1995, Retired
2. Jing-Yang Mu, 1996, in CA,
USA
3.
Ke Zhang, 1997, bioinformatic scientist at Ceres Inc., CA,
(http://www.ceres-inc.com).
4.
Niclas Karlsson 1997, professor,
Oslo.
5.
Rein Sikut, 1998, head of immunology group at a Biotech. company
6.
Noomi Asker, 1998. Reseacher.
7. Magnus Axelsson, 1999, Clinical Chemistry,
8.
Kristina Thomsson, 2000, at Proteomics Core Facility
9.
Fredrik Olson, 2002. Private compant
10.
Christian Andersson 2003, AstraZeneca, Gothenburg
11.
Sirle Laos 2005, Researcher Barcelona, Spain
12. Martin Lidell 2006, universitetslektor
at Dept. MedicalBiochemistry
13.
Emily Malmberg, 2006, Scientist
14.
Jessica Holmén Larsson, 2006, AstraZeneca, Gothenburg
15.
Tiange Lang, 2007, independent posion in China
16.
Malin E.V. Johansson, June 2009, PI, Professor, Medical Biochemistry, at MBG
17.
Jenny Gustafsson, May 2012, Shared with Henrik
Sjövall, PI, Starting
grant VR, at Dept. Physiology, at MBG.
18.
Thaher Pelaseyed, Nov. 2012, PI, Researcher, SSMF, at MBG.
19.
Joakim Bergström, Dec. 2014, Lab. Director at AstraZeneca
20. Sjoerd van der Post, Dec. 2014, PI, post-doc position
VR, at MBG.
21. Karolina Sjöberg Jabbar, Nov.
2018, post-doc positio VR
at Dept. Medicine, Univ. Gothenburg
Former
and current international and national Post-docs
in the laboratory:
1.Daniella
Steel (from
2.
Rein Sikut (from
3.
Klaus Godl, (from
4.
Julia Fernandez-Rodrigues Univ. Vigo, from
5.
Cristina Weinberg (from
6.
Malin Bäckström, Univ. Gothenburg, head at Mamalian
Protein Expression Core Facility
7.
Elin Grahn, Univ. Gothenburg, at Örebro University
8.
Kristina Thomsson, Univ. Gothenburg, Proteomics Core Facility
10.
Iris Härd, Karolinska Inst., left science.
11. Ana Rodriguez Pinero, Vigo University Spain, AstraZeneca
12.
Thaher Pelaseyed, established his own lab. at Dept.
13.
14.
Babu Sharamsha, India, post-doc. at UNC Chapell Hill,
NC
15.
Jessica Holmen Larsson, researcher at Clinical Neuroscience, Univ. Gothenburg
16.
Malin EV Johansson, Univ. Gothenburg, established her own laboratory 2014, in
MBG
17.
Anna Ermund, Lund University, Scientist in my lab.
18.
Sjoerd van der Post, PI, on VR Starting grant, in MBG
19.
Harriet Nilsson, deceased
20.
Catharina Wising, Sweden, Scientist in industry.
21.
Andre Shutte, Germany, Germany
22.
Christian Recktenwald, Germany, Scientist in my lab.
23. Hedvig Jakobsson, Sweden, scientist at clinical
microbiology
24.
Liisa Arike, Tallin, Estonia, Scientist at Mass spectrometry Core Facility
25.
George Birchenough, London, UK, PI, VR, Wallenberg Center, in MBG
26.
Evelin Berger, Germany, Proteomics core facility, Gothenburg
27.
Hannah Schneider, Germany, Scientist at Astra-Zeneca
28.
Lisa Wuerner, Germany, Scientific writer
29.
Jenny Gustafsson, Sweden, PI Dept. Physiology, Gothenburg, in MBG
30.
Joan Fernandez, Spain, University Teacher Spain.
31.
Joakim Bergström, Sweden, Scientist at AstraZeneca.
32.
Sergio Tillo Muyo, Spain, Scientist in my lab.
33. Brendan Dolan, Dublin, Ireland, Scientist in my
lab.
34. Dalia Fakih, Beirut, Lebanon, Scientist at AstraZeneca.
35. Aaran Lewis, London, UK, To industry
36. Melania Giorgetti, Italy, Pharmacy Industry
37. Pablo Gallego, Spain, Scientist
at AstraZeneca
38. Maria José Bonete, Spain, Scientist
at Spanish University
39. Ana S. Luis, Portugal, PI, VR start, in MGB
Senior visiting Scientist
working in my laboratory
1. Dr. Jean-Francois Bouhours (from
France), 1998-1999
2. John R. Riordan (from
3. Prof. Sandra J. Gendler (from
4. Prof. Carlos Flores (from Chile) 5 month 2018
Current staff in
the laboratory
4
Senior scientists
Two nurses 50%
External PhD. examiner
1. Peter Aagaard-Nielsen, 1997,
Copenhagen, Denmark
2.
Helle Hassan, 1999, Copenhagen, Denmark
3.
Torunn Thingstad 2000,
4.
Hans Wandall, 2004, Copenhagen, Denmark
5.
Mads Peter Agervig Tarp, 2006, Copenhagen, Denmark
6.
Susan McNally, 2010, Dublin, Ireland
7.
Zang Yand, 2012, Århus, Denmark
8.
Vignesh Venkatakrishnan, 2014, Sydney, Australia
9.
Elisabeth Haugstad, 2015, Trondheim, Norway
10. Marlene Andersson, 2016, Uppsala, Sweden
11.
Benoit Chassaing, 2019, HDR defense, Paris, France
12.
Thomas Daugbjerg Madsen, 2021, Copenhagen, Denmark
Companies
Founded
MucoMedics AB and MucoLife
AB
Patents
1. USE OF ALGINATE OLIGOMERS IN THE TREATMENT OF CYSTIC
FIBROSIS AND OTHER CONDITIONS ASSOCIATED WITH DEFECTIVE CFTR ION CHANNEL
FUNCTION, US Patent: DEHN40.006APC
2. A PROTEIN BASED ON ZG16 TO BE USED AS A MEDICAMENT, EU
patent granted 15 798 074.9.
3. Calcium binding compounds
based on gammacarboxy glutamate. US Patent 10,035,821
B2, European EPO EP3311829